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Summary
Sheehan’s syndrome is postpartum hypopituita-
rism resulting from pituitary necrosis due to seve-
re hypotension or shock secondary to massive
bleeding during or following delivery. Sheehan’s
syndrome is one of the neglected endocrine disor-
ders. Although the definite mechanisms have not
been clearly defined; disturbed blood supply of the
pituitary gland due to hypotension in addition to in-
creased demand of the gland due to physiological
enlargement during gestation, relatively small sel-
la size and autoimmunity in the longterm are sug-
gested factors that are involved in the pathogene-
sis. Sheehan’s syndrome is characterized by vari-
able degrees of hypopituitarism. Patients may have
isolated, partial or complete hypopituitarism and
they present with symptoms or signs due to the de-
ficient hormone(s). The main difference from hypo-
pituitarism due to other causes, such as pituitary
adenoma or pituitary surgery, is the severity of the
hormonal insufficiency. The symptoms and signs
depend on the type and the severity of the underl-
ying hormonal insufficiency. A history of failure of
postpartum lactation and resumption of normal
menses are the most common diagnostic features
suggesting Sheehan’s syndrome. Partial or com-
plete empty sella on MRI or CT is almost always se-
en in the patients. Treatment includes appropriate
replacement of deficient hormones.
KEY WORDS: postpartum hypopituitarism; Sheehan’s
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Introduction
Sheehan’s syndrome refers to postpartum hypopituita-
rism resulting from pituitary necrosis due to severe
hypotension or shock secondary to massive bleeding
during or following delivery. Sheehan’s syndrome is one
of the neglected endocrine disorders. It was first descri-
bed by HL Sheehan in 1937 (1). Because of its rarity in
Western Society, it has become a forgotten disorder
supposed to be seen only in underdeveloped countries
in which obstetrical care is not adequate and treatment
options to prevent the development of the syndrome are
not available. Nowadays, doctors including endocrinolo-
gists are not given sufficient information regarding Shee-
han’s syndrome during their medical education, so they
are not aware of its clinical presentation. For this reason,
most patients with Sheehan’s syndrome are unrecogni-
zed and thereby untreated for a long time until admitted
to the emergency departments in a poor condition due to
the complication of severe hypopituitarism. During the
last decades social and economical problems have cau-
sed a huge amount of immigration from underdeveloped
and poor countries to more developed and richer coun-
tries. Patients with subtle hypopituitarism due to Shee-
han’s syndrome among immigrants are not correctly di-
agnosed because medical staff are unaware of the
syndrome. Some of these patients are diagnosed by im-
migrant doctors who have seen patients with similar
symptoms previously in their homeland. So, obviously,
the prevalence of Sheehan’s syndrome in Western So-
ciety is underestimated. Supporting this idea, recent da-
ta from a European study in which 1034 patients were
enrolled in the KIMS-Pfizer International Metabolic Data-
base the majority of whom were European in origin, sho-
wed that the prevalence of Sheehan’s syndrome was
3.1%, making it the sixth most common cause of adult
GH deficiency (2). Another study from Iceland, a Euro-
pean country in which the obstetrical care is undoub-
tedly modern, showed a prevalence of 5.5 per 100, 000
in the Icelandic population (3). The highest prevalence
of Sheehan’s syndrome nowadays is reported in India;
in one study it was calculated that the projected number
of women with Sheehan’s syndrome among a total po-
pulation of parous females aged  ≥ 20 years (12, 32,
827) would be 38, 691 in the Kashmir valley (4). In a
very recent study from France, 39 patients with Shee-
han’s syndrome were reported and they experienced a
long diagnostic delay (5).
Sheehan’s syndrome is probably the most common
cause of hypopituitarism in underdeveloped countries.
In some developing countries, including Turkey, the
presence of Sheehan’s syndrome is still due to relati-
vely late diagnosis in patients who had peri or postpar-
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tum bleeding leading to pituitary necrosis a long-time
ago; for example 20-30 years ago. Another important
factor revealing unrecognized cases is the increasing
number of experienced medical staff who are familiar
with Sheehan’s syndrome. 
Clinical Picture
Sheehan’s syndrome is characterized by variable deg-
rees of hypopituitarism. Patients may have isolated,
partial or complete hypopituitarism and they present
with symptoms or signs due to the deficient hormone
(s). The main difference from hypopituitarism due to ot-
her causes, such as pituitary adenoma or pituitary sur-
gery, is the severity of the hormonal insufficiency. For
example GH deficiency is more severe in Sheehan’s
syndrome patients than in patients with non-functional
pituitary adenoma (6). The frequency of panhypopitui-
tarism was reported as 55-86% and GH deficiency was
diagnosed almost always in all patients with Sheehan’s
syndrome (6-8). The diagnosis of Sheehan’s syndrome
is usually made in patients months to years later. The
symptoms and signs depend on the type and the seve-
rity of the underlying hormonal insufficiency. A history
of failure of postpartum lactation and resumption of
normal menses are the most common diagnostic featu-
res suggesting Sheehan’s syndrome. We proposed the
following criteria for the diagnosis of Sheehan’s
syndrome: 1-Typical obstetrical history of severe post-
partum vaginal bleeding, 2-Severe hypotension or
shock which requires blood transfusion or fluid replace-
ment, 3-Failure of postpartum lactation, 4-Failure to re-
sume regular menses after delivery, 5-Varying degrees
of anterior pituitary failure, 6-Empty sella on CT scan or
MRI (9). Most patients may have subtle hypopituitarism
characterized by nonspecific manifestations including
fatigue, weakness, mild hypotension, cold intolerance
and feeling unwell. These patients may remain undiag-
nosed or misdiagnosed for a long time and receive
inappropriate treatments such as vitamin supplementa-
tion and antidepressive agents. Therefore, the clinical
presentation in the majority of patients with Sheehan’s
syndrome is subclinical and at least some of them are
seen for the first time in emergency departments in a
hypoglycemic and/or hypocortisolemic state after they
have been subjected to a stressful condition such as
an infection which may result in coma and death.
Sheehan’s syndrome accounted for 8% of 126 patients
hospitalized because of hypoglycemia in one university
hospital. It was the 7th most common cause of
hypoglycemia (10). The signs and symptoms of Shee-
han’s syndrome are shown in Table 1. Hypothyroidism
in Sheehan’s syndrome is usually less severe than pri-
mary hypothyroidism and some findings such as facial
edema and periorbital puffiness are not present in
Sheehan’s syndrome patients. Hypopigmentation ins-
tead of hyperpigmentation may be seen in patients with
Sheehan’s syndrome. Fine wrinkling around the eyes
and mouth presumably due to long-term GH and estro-
gen deficiencies create the typical appearance of a pa-
tient with Sheehan’s syndrome. Differential diagnosis
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of Sheehan’s syndrome should include spontaneous
infarction of a pituitary adenoma due to hypotension
during or after delivery in which decompressive sur-
gery may be necessary, autoimmune hypophysitis
which may result in empty sella as a final outcome and
primary empty sella syndrome (11,12).
Pathogenesis
Although the definite mechanisms responsible for the
development of postpartum pituitary necrosis have not
been clearly defined, recent data have given new in-
sight into the pathogenesis. The pituitary gland is
physiologically enlarged during pregnancy (13). Blood
supply may be compressed because of an enlarged pi-
tuitary gland and decreased sella size which has been
reported in most of patients with Sheehan’s syndrome
(9,12,14). Blood flow to the pituitary may be comprimi-
sed due to vasospasm following untreated severe
hypotension associated with hemorrhage. All these
factors make the pituitary more susceptible to ischemia
in a pregnant woman (9,12,15). Pituitary dysfunction in
Sheehan’s syndrome may worsen over the years. For
this reason the clinical picture is generally worse when
Sheehan’s syndrome is diagnosed. One of the anterior
pituitary hormones which is normal at the beginning
may be lost during the course of the syndrome. There-
fore, it would be expected that an autoimmune process
may be involved in the worsening of pituitary dysfunc-
tion. Some studies suggest that antipituitary antibodies
(APAs) may be detected in the circulation of patients
with Sheehan’s syndrome (16-18). On the other hand,
Goswami et al. reported that sequestered antigens due
to tissue necrosis which could trigger autoimmunity
may be responsible for the delayed hypopituitarism se-
en in Sheehan’s syndrome (17). In order to understand
Table 1 - The manifestations of Sheehan’ syndrome.
1. Agalactia
2. Amenorrhea
3. Infertility
4. Hypotension
5. Psychiatric disorders
6. Intolerance to fasting/hypoglycaema
7. Weakness
8. Tiredness
9. Breast atrophy
10. Fine wrinkling on the face
11. Loss of hair
12. Cold intolerance
13. Empty sella (partial or complete) on MRI
14. Cognitive dysfunction
15. Sleep disorders (more non REM and less REM sleep)
16. Skin abnormalities (decreased sebum content and skin
hydration)
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whether an autoimmune process can contribute to late
hypopituitarism, we evaluated the presence of antihy-
pothalamic antibodies (AHAs) and APAs in 20 women
with Sheehan’s syndrome and found AHA positivity in
40% and APA positivity in 35% of the patients. These
results clearly suggest that an autoimmune process in-
volving both the hypothalamus and pituitary gland may
contribute to late pituitary dysfunction in Sheehan’s
syndrome (19). On the other hand, Atmaca et al. repor-
ted that Sheehan’s syndrome is characterized by a
marked variation in some peripheral lymphocytes cell
subsets indicating altered immune regulation (20).
Prothrombin time and INR are increased in Sheehan’s
patients when compared to normal women which might
suggest that coagulation abnormalities may be one of
the predisposing factors of postpartum hemorrhage
(21-23). The pathogenesis of Sheehan’s syndrome is
shown in Figure 1.
Posterior pituitary functions
Previous autopsy studies showed that in over 90% of
patients with Sheehan’s syndrome the posterior lobe of
the pituitary gland and hypothalamic nuclei were atrop-
hic (24,25). Posterior pituitary functions have not been
extensively investigated in patients with Sheehan’s
syndrome. Another reason for the lack of data regar-
ding posterior pituitary function is that only a few pati-
ents with Sheehan’s syndrome may present with overt
diabetes insipidus (26-28). We and others have repor-
ted that there are subtle defects in posterior pituitary
functions and partial diabetes insipidus is more com-
mon than expected (29,30). We have also found that
the threshold for thirst perception was increased in
Sheehan’s syndrome patients and plasma osmolalities
at baseline and after hypertonic saline infusion were
significantly higher in patients than in control women.
On the other hand, GH replacement therapy for 3
months did not reverse the mildly deteriorated posteri-
or pituitary functions (31). Hyponatremia is not uncom-
mon and the main causes are untreated adrenal failu-
re and inappropriate vasopressin secretion (Tab. 2).
Laboratory Investigation
In the investigation of anterior pituitary function in pati-
ents suspected with Sheehan’s syndrome the first step
is the measurement of basal hormone levels which
may be sufficient to diagnose Sheehan’s syndrome in
some patients who have typical obstetrical history. Ho-
Sheehan’s syndrome
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Figure 1.  Pathogenesis of Sheehan’s syndrome.
Table 2 - Water and electrolyte disturbances in Shee-
han’s syndrome.
1. Central diabetes insipidus
2. Partial diabetes insipidus
3. Increased threshold for thirst perception
4. Hyponatremia
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wever most patients may require dynamic pituitary
function tests including insulin tolerance test, ACTH sti-
mulation test, glucagon stimulation test, a GHRH-argi-
nine stimulation test because a diagnosis of subclinical
hypopituitarism may not be possible with basal hormo-
ne measurement alone. Currently the TRH stimulation
test used to diagnose central hypothyroidism and
hypoprolactinemia has ceased to be used since very
sensitive TSH assays have become commonly avai-
lable. However it was shown that when both free T3
and TSH levels were in the low-normal ranges the TRH
stimulation test may be helpful in the diagnosis (32).
Partial or complete empty sella on MRI or CT is almost
always seen in all patients with Sheehan’s syndrome.
MRI is the preferred radiological procedure for imaging
of the hypothalamo-pituitary region in Sheehan’s
syndrome patients.
Treatment 
Treatment of a patient with Sheehan’s syndrome is not
different from that of a patient with hypopituitarism due
to other causes. Deficient hormones should be repla-
ced appropriately. Thyroid hormone and glucocorticoid
replacement therapy is crucially important if they are
deficient. Replacement therapy including estrogen and
progesterone depends on the menopausal status of
the patient; premenopausal women with Sheehan’s
syndrome require estrogen and progesterone replace-
ment therapy unless there is a contraindication. Estro-
gen and progesterone replacement therapy in hypogo-
nadal postmenopausal women with Sheehan’s syndro-
me is controversial but the current data are not in favor
of this treatment because of the side effects, including
thromboembolic events in particular. One of the most
controversial issues regarding replacement therapy is
related to GH replacement therapy (GHRT). We have
extensively investigated the effects of GHRT on diffe-
rent parameters in patients with Sheehan’s syndrome
(33). Only severely GH deficient patients are suitable
candidates for GHRT. We have reported that GHRT
has beneficial effects on cognitive functions as detec-
ted by the latency of P300 auditory potentials (34).
It was shown that GH replacement therapy has benefi-
cial effects on Quality of Life, body composition and the
lipid profile (6). GHRT for 6 months is not sufficient to
improve disturbed sleep architecture due to severe GH
deficiency in Sheehan’s syndrome patients (35). Six
months of GHRT may improve sebum content which is
reported to be decreased on the forehead (36). On the
other hand, we also reported that GHRT in severely
GH deficient patients, most of whom had Sheehan’s
syndrome, improves sympathetic tone which is decrea-
sed in severe GH deficiency, without an obvious
arrhythmogenic effect (37).
Conclusion
We think that the prevalence of Sheehan’s syndrome
in the modern age, which is characterized by enormo-
us development in health care and of course in obstet-
rical care, is underestimated. Two simple questions as
to whether the patient failed to lactate and failed to re-
sume menstruation after delivery are crucially impor-
tant and these questions should be routinely asked
when taking medical history. The most important thing
is that doctors should be aware of Sheehan’s syndro-
me. Thereby, most patients may be diagnosed prom-
ptly without delay. Otherwise, unrecognized and un-
treated patients may have increased morbidity and
mortality due to chronic hypopituitarism.
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